Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2024-212973

Published: 2024

Journal Articles

Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up

Jan A. Burger, Neil E. Kay, John N. Allan, Paul M Barr, Jacqueline C. Barrientos, Carolyn Owen, Victoria Wang, Hsin-Hui Huang, Lynne Neumayr, Christopher Abbazio, Gabriel S. Krigsfeld, Sneh Mody, Paolo Ghia, Tait D. Shanafelt

Blood (2024) 144 (Supplement 1): 4615.

https://doi.org/10.1182/blood-2024-194382

Published: 2024

Journal Articles

Hepatocyte Growth Factor Is Overexpressed in AML and Remodels the Mesenchymal Stromal Cell Niche

Annika Chura, Wantong Li, Konur Oyman, Victoria Wang, Bradley Wayne Blaser

Blood (2024) 144 (Supplement 1): 4067.

https://doi.org/10.1182/blood-2024-211681

Published: 2024

Journal Articles

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Despoina Papazoglou, Xin Victoria Wang, Tait D. Shanafelt, Connie E. Lesnick, Nikolaos Ioannou, Giulia De Rossi, Sylvia Herter, Marina Bacac, Christian Klein, Martin S. Tallman, Neil E. Kay, Alan G. Ramsay

Blood (2024) 143 (1): 57–63.

https://doi.org/10.1182/blood.2023020554

Published: 2024

Includes: Supplemental data

Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood (2022) 140 (2): 112–120.

https://doi.org/10.1182/blood.2021014960

Published: 2022

Includes: Supplemental data

Journal Articles

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Blood (2021) 138 (26): 2810–2827.

https://doi.org/10.1182/blood.2020010146

Published: 2021

Includes: Supplemental data

Journal Articles

Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

Blood (2021) 138 (Supplement 1): 1562.

https://doi.org/10.1182/blood-2021-150462

Published: 2021

Journal Articles

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Blood (2021) 138 (11): 948–958.

https://doi.org/10.1182/blood.2020010144

Published: 2021

Includes: Supplemental data

Journal Articles

Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)

Amer M. Zeidan, MBBS, MHS, Victoria Wang, Jerald P. Radich, MD, Jan Philipp Bewersdorf, MD, Vijaya R. Bhatt, MD, Elad Sharon, MD MPH, Steven D. Gore, MD, Selina M. Luger, MD FRCPC, Mark Litzow, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-137734

Published: 2020

Journal Articles

Analysis of Multiplexed Single Cell RNA Sequencing Clinical Correlative Data in AML Reveals Biomarkers of Resistance

Charalambos Andreadis, MD, Tommy Jiang, Victoria Wang, Ravi Patel, PhD, Arjun Rao, PhD, Chun Jimmie Ye, PhD, Bradley W Blaser, MD PhD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-141622

Published: 2020

Journal Articles

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

Ramya Ramaswami, Kathryn Lurain, Cody J. Peer, Anna Serquiña, Victoria Wang, Anaida Widell, Priscila Goncalves, Seth M. Steinberg, Vickie Marshall, Jomy George, William D. Figg, Denise Whitby, Joseph Ziegelbauer, Thomas S. Uldrick, Robert Yarchoan

Blood (2020) 135 (25): 2316–2319.

https://doi.org/10.1182/blood.2019004602

Published: 2020

Includes: Supplemental data

Journal Articles

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Blood (2019) 134 (Supplement_1): 33.

https://doi.org/10.1182/blood-2019-126824

Published: 2019

Journal Articles

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Tait D. Shanafelt, MD, Victoria Wang, Neil E. Kay, MD, Curtis A. Hanson, MD, Susan M. O'Brien, MD, Jacqueline C Barrientos, MD, Harry P. Erba, MDPhD, Richard M. Stone, MD, Mark R. Litzow, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): LBA-4.

https://doi.org/10.1182/blood-2018-120779

Published: 2018

Journal Articles

Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial

Despoina Papazoglou, BSc, Connie E. Lesnick, Victoria Wang, Neil E. Kay, MD, Tait D. Shanafelt, MD, Alan G. Ramsay, BSc,MSc,PhD

Blood (2018) 132 (Supplement 1): 236.

https://doi.org/10.1182/blood-2018-99-118333

Published: 2018

Journal Articles

Changes in Subcellular Localization of GSK3β As a Novel Driver of AML

James ignatz-Hoover, Isaac Ghansah, Masumi Ueda, MD, Victoria Wang, Hillard M Lazarus, MD, Marcos de Lima, MD, David Wald, PhD MD

Blood (2017) 130 (Supplement 1): 1226.

https://doi.org/10.1182/blood.V130.Suppl_1.1226.1226

Published: 2017

Journal Articles

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Esteban Braggio, PhD, Victoria Wang, Laura Ann Bruins, BS, Santiago Barrio, PhD, Connie Lesnick, Jacqueline C. Barrientos, MD, Susan M. O'Brien, MD, Martin S. Tallman, MD, Mark R. Litzow, MD, Rafael Fonseca, MD, Neil E. Kay, MD, Tait D Shanafelt, MD

Blood (2017) 130 (Supplement 1): 4288.

https://doi.org/10.1182/blood.V130.Suppl_1.4288.4288

Published: 2017

Journal Articles

A Phase I Dose Finding Trial of Eltrombopag during Consolidation Therapy in Adults with Acute Myeloid Leukemia Employing a Unique Dosing Design: PrE0901, a Precog Study

Stephen A. Strickland, Hillard M. Lazarus, MD, Xin Victoria Wang, PhD, Jan Cerny, MD PhD, Witold B. Rybka, MD, Martin S. Tallman, MD, Mark R. Litzow, MD

Blood (2016) 128 (22): 4053.

https://doi.org/10.1182/blood.V128.22.4053.4053

Published: 2016

Journal Articles

A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906

Mark R. Litzow, MD, Xin Victoria Wang, PhD, Martin P. Carroll, MD, Judith E. Karp, MD, Rhett Ketterling, MD, Scott H. Kaufmann, MD PhD, Hillard M. Lazarus, Selina M. Luger, MD, Elisabeth M. Paietta, PhD, Jacob M. Rowe, MD, Jessica K Altman, Keith W Pratz, MD, E. Randolph Broun, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 3742.

https://doi.org/10.1182/blood.V124.21.3742.3742

Published: 2014

Journal Articles

Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease

Thomas S. Uldrick, Mark N. Polizzotto, Karen Aleman, Kathleen M. Wyvill, Vickie Marshall, Denise Whitby, Victoria Wang, Stefania Pittaluga, Deirdre O’Mahony, Seth M. Steinberg, Richard F. Little, Robert Yarchoan

Blood (2014) 124 (24): 3544–3552.

https://doi.org/10.1182/blood-2014-07-586800

Published: 2014

Includes: Supplemental data

Journal Articles

Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease

Mark N. Polizzotto, Thomas S. Uldrick, Victoria Wang, Karen Aleman, Kathleen M. Wyvill, Vickie Marshall, Stefania Pittaluga, Deirdre O’Mahony, Denise Whitby, Giovanna Tosato, Seth M. Steinberg, Richard F. Little, Robert Yarchoan

Blood (2013) 122 (26): 4189–4198.

https://doi.org/10.1182/blood-2013-08-519959

Published: 2013

Includes: Supplemental data

NARROW

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up

Hepatocyte Growth Factor Is Overexpressed in AML and Remodels the Mesenchymal Stromal Cell Niche

Ibrutinib-based therapy reinvigorates CD8 + T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Analysis of Multiplexed Single Cell RNA Sequencing Clinical Correlative Data in AML Reveals Biomarkers of Resistance

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial

Changes in Subcellular Localization of GSK3β As a Novel Driver of AML

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

A Phase I Dose Finding Trial of Eltrombopag during Consolidation Therapy in Adults with Acute Myeloid Leukemia Employing a Unique Dosing Design: PrE0901, a Precog Study

A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906

Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease

Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only